Boston Scientific (BSX) Q3 Earnings and Revenues Top Estimates

Boston Scientific (BSX) reported robust quarterly results, with adjusted earnings of $0.75 per share, exceeding the Zacks Consensus Estimate of $0.71 by 5.63%, and revenues of $5.07 billion, surpassing estimates by 1.94%. This marks the fourth consecutive quarter the medical device manufacturer has beaten both EPS and revenue expectations. Despite its year-to-date stock performance lagging the S&P 500, the company maintains a favorable Zacks Rank #2 (Buy) driven by positive estimate revisions, with future consensus estimates projecting Q4 EPS of $0.76 and full-year revenues of $19.85 billion.

Analysis

Boston Scientific (BSX) delivered strong financial results for the quarter ended September 2025, reporting adjusted earnings of $0.75 per share, which surpassed the Zacks Consensus Estimate of $0.71 by 5.63%. This represents a significant increase from $0.63 per share a year ago. Quarterly revenues also exceeded expectations, reaching $5.07 billion against an estimate of $4.97 billion, marking a 1.94% beat and an increase from $4.21 billion in the prior year. This performance extends a consistent trend, as the company has now beaten both EPS and revenue consensus estimates for four consecutive quarters.

Despite this operational strength, BSX shares have underperformed the broader market year-to-date, with an 11.9% gain compared to the S&P 500's 14.5%. However, the company's near-term outlook appears favorable, evidenced by a Zacks Rank #2 (Buy) driven by positive earnings estimate revisions. Current consensus estimates project Q4 EPS of $0.76 on $5.16 billion in revenues, and full-year revenues of $19.85 billion.

A potential headwind for BSX is its industry classification; the Medical - Products industry is currently in the bottom 42% of Zacks-ranked industries. Historically, top-ranked industries significantly outperform lower-ranked ones, suggesting a possible drag on stock performance despite robust company-specific results. The sustainability of immediate price movements will heavily depend on management's commentary during the upcoming earnings call, which will provide crucial insights into future expectations and guidance.

The article also briefly mentions Envista (NVST), another company in the same industry, which is expected to report Q3 2025 earnings of $0.27 per share, a 125% year-over-year increase, on revenues of $638.02 million. However, its consensus EPS estimate has seen a slight 0.5% downward revision over the last 30 days, contrasting with BSX's favorable revision trend.

Key Decisions for Investors

• Monitor management's commentary on the earnings call for forward guidance and any shifts in the positive earnings estimate revisions, which are key drivers for near-term stock movement.
• Evaluate BSX's performance relative to its industry peers, considering the Medical - Products industry's current bottom-tier ranking, which could present a sector-specific headwind despite strong company fundamentals.
• Consider the stock's consistent earnings and revenue beats as a sign of operational strength, but balance this against its year-to-date underperformance relative to the broader S&P 500.